What is Illumina's (ilmn) stock price potential in the next year?
Their forecasts range from $340.00 to $570.00. On average, they expect Illumina's stock price to reach $441.17 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
Where can I buy Illumina Inc (ilmn)?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Illumina's stock price today?
What is the target price for Illumina?
Their forecasts range from $340.00 to $570.00. On average, they expect Illumina's stock price to reach $441.17 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View analysts' price targets for Illumina or view top-rated stocks among Wall Street analysts. Who are Illumina's key executives?
What are analysts'target prices for Illumina's stock?
13 equities research analysts have issued 1-year target prices for Illumina's stock. Their predictions range from $280.00 to $370.00. On average, they expect Illumina's stock price to reach $328.7273 in the next twelve months.
See more
Is ILMN a buy or sell?
Out of 8 analysts, 2 (25%) are recommending ILMN as a Strong Buy, 0 (0%) are recommending ILMN as a Buy, 4 (50%) are recommending ILMN as a Hold, 0 (0%) are recommending ILMN as a Sell, and 2 (25%) are recommending ILMN as a Strong Sell.
Does Illumina stock pay dividends?
Illumina (NASDAQ: ILMN) does not pay a dividend.
Why is Illumina dropping?
Shares of Illumina were falling sharply Friday after the gene-sequencing supplier said that Sam Samad would be departing as its chief financial officer. Samad will leave Illumina (ticker: ILMN) on July 8, after serving as CFO for more than five years, the company said in a news release.
Is Illumina undervalued?
Illumina retains a regular Real Value of $250.12 per share. The prevalent price of the firm is $189.21. At this time, the firm appears to be undervalued....Diagnostics & Research.LowTarget PriceHigh340.00440.36570.00
How do I buy Illumina stock?
Illumina common stock can be bought or sold through a stockbroker, bank or financial institution that offers brokerage services.
Who owns Illumina?
Francis deSouzaIllumina, Inc.TypePublicKey peopleFrancis deSouza (President & CEO) John W. Thompson ( Board Chair) Sam Samad (CFO)ProductsNovaSeq 6000, HiSeq X, HiSeq 4000, MiSeq, MiSeqDx, MiniSeq, iSeq 100, NextSeq 550, NextSeq 550Dx, iScanRevenueUS$4.53 billion (2021)Operating incomeUS$−0.12 billion (2021)12 more rows
Is Meta a good stock to buy?
Ultimately, according to BofA's analysis, Meta shares are valued too cheaply for a company with its financial resources. The stock currently trades at 12 times estimated 2023 earnings per share, compared to the S&P 500's 14.5 times, according to FactSet.
Is Illumina a good place to work?
Company Culture at Illumina 87% of employees at Illumina say it is a great place to work compared to 57% of employees at a typical U.S.-based company. Source: Great Place to Work® 2021 Global Employee Engagement Study.
Should I sell Illumina?
There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +31.66% increase from the last price of 82.41.
What is Illumina valuation?
What is Illumina Inc?
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and ...
About Illumina
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
Headlines
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Illumina (NASDAQ:ILMN) Frequently Asked Questions
Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?
Nasdaq Global Select
10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock.
Environmental, Social, and Governance Rating
The company develops, manufactures, and markets next-generation life-science tools and integrated systems to analyze genetic variations and biological functions.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
What is Illumina's business?
The company develops, manufactures, and markets next-generation life-science tools and integrated systems to analyze genetic variations and biological functions.
What is Illumina's high throughput?
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also se
